Nature Medicine, Published online: 23 April 2024; doi:10.1038/s41591-024-02942-7
In a phase 2 trial, nivolumab achieved a response rate of 58% in patients with mismatch-repair-deficient gynecological cancers, meeting the primary endpoint, and genomic and immunologic features correlated with response.
Comments
No Trackbacks.